CCL2 and neoplasm: The Amela tumor signature shares many genes with the innate anti-PD1 resistance (IPRES) signature that was recently described in human melanomas resisting anti-PD1 therapy, including EMT-like genes (Axl, Twist2, Loxl2), angiogenesis genes (Vegfa) and monocyte/macrophage recruitment genes (Ccl2, Ccl7)3, 5.